Shire Wins U.S. Court Ruling Upholding Patents on Vyvanse

Shire Plc won a U.S. court ruling blocking generic versions of its best-selling product, the Vyvanse treatment for attention deficit hyperactivity disorder.

U.S. District Judge Stanley R. Chesler in New Jersey found that Shire’s patents on the drug are valid and would be infringed if five generic-drug companies introduced copies of the medicine, Shire said in a statement today.

Unless the generic companies win an appeal, they will be blocked from introducing a copy of the drug until the patents expire in 2023, Dublin-based Shire said. Shire sued the companies after they filed for approval from the U.S. Food and Drug Administration to make copies of Vyvanse.

The generic companies sued by Shire are Actavis Plc, Amneal Pharmaceuticals LLC, Mylan Inc., Roxane Laboratories Inc., and Novartis AG’s Sandoz Inc.

Vyvanse had sales of $1.2 billion last year. Shire is the subject of an unsolicited, 27.3 billion-pound ($46.4 billion) takeover proposal from AbbVie Inc.

Shire shares rose 0.7 percent to 44.33 pounds at 8:18 a.m. in London.

Before it's here, it's on the Bloomberg Terminal.